AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are getting enthusiastic again after the biotech firm’s Phase 3 IAP312 clinical trial of Zalviso, approved in the …
Yesterday, drug maker Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced the beginning of Phase 3 trial AURORA of voclosporin, a medicine intended to treat lupus …
Last week, on April 20, during the National Kidney Foundation 2017 Spring Clinical Meeting in Orland, Florida, Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) announced some …
H.C.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are currently rising almost 8% after the biotech firm released the rare, good news that its drug in …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) revealed yesterday evening that its Board of Directors has chosen Dr. Richard Glickman, the biotech firm’s founder and Chairman, …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) just scored what H.C.
On Tuesday, Galectin Therapeutics Inc (NASDAQ:GALT) reported that its pipeline investigational drug GR-MD-02, designed to treat liver fibrosis, missed its primary endpoint in …
AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) just announced positive top-line results from its third, final Phase 3 trial of pipeline drug ARX-04 designed to treat …
